DUSA signs research agreements with Massachusetts General Hospital.MISSISSAUGA, Ontario--(HealthWire)--March 22, 1996--DUSA Pharmaceuticals Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. :DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area ; TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :DSP) announced the signing of two new agreements with the Massachusetts General Hospital Massachusetts General Hospital Health care The major teaching hospital for Harvard Medical School, widely regarded as one of the best health care centers in the world (MGH), sponsoring independent investigator research on the use of ALA Photodynamic Therapy (PDT) for permanent hair removal, and ALA Photodiagnosis (PD) for detection of bladder cancer. The first study, directed Rox Anderson, MD, of the Wellman Laboratories of Medicine at the MGH, is aimed at optimizing methods of ALA application for human hair removal using ALA PDT. The second study, directed by Thomas Deutsch, PhD, also of the MGH Wellman Laboratories, will examine the use of ALA-induced fluorescence for the diagnosis of malignant bladder lesions. DUSA is developing ALA PDT as a method of hair removal following a human pilot treatment study conducted last year at the MGH by Dr. Anderson and Melanie Grossman, MD. The company is developing ALA for the photodiagnosis of bladder cancer based on the results of previously published independent European studies, which showed the selective accumulation of fluorescence in human bladder tumors and pre-cancerous lesions following ALA application. DUSA is planning to conduct its own clinical trials in 1996 on both of these indications. DUSA Pharmaceuticals Inc. is a development stage New Jersey company engaged primarily in the development of proprietary methods of Photodynamic Therapy (PDT) and Photodiagnosis (PD) utilizing five-aminolevulinic acid (ALA). PDT is a two step medical treatment which combines the use of a pharmaceutical compound with exposure to light to induce a therapeutic effect. CONTACT: DUSA Pharmaceuticals, Mississauga D. Geoffrey Shulman, MD, FRCPC FRCPC Fellow of the Royal College of Physicians and Surgeons of Canada 905/677-4554 (phone) 905/677-5240 (fax) |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion